Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.

doi:10.1002/ajh.26694

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.

American journal of hematology - 1 Nov 2022

Lachowiez Curtis A, Reville Patrick K, Kantarjian Hagop, Jabbour Elias, Borthakur Gautam, Daver Naval, Issa Ghayas, Furudate Ken, Tanaka Tomoyuki, Pierce Sherry, Tang Guilin, Patel Keyur P, Medeiros Jeffrey, Abbas Hussein A, Haddad Fadi, Hammond Daniel, Short Nicholas J, Maiti Abhishek, Yilmaz Musa, Sasaki Koji, Takahashi Koichi, Pemmaraju Naveen, Konopleva Marina, Garcia-Manero Guillermo, Ravandi Farhad, Kadia Tapan M, Loghavi Sanam, DiNardo Courtney D

Abstract excerpt

Isocitrate dehydrogenase 1 or 2 (IDH1 or IDH2) mutations occur frequently in newly diagnosed (ND) acute myeloid leukemia (AML) often with co-occurring NPM1 mutations, which may influence treatment outcomes. Detailed analysis of IDH-mutated AML treated with venetoclax and influence of co-occurring NPM1 mutations remains unclear. This retrospective single-center cohort study evaluated clinical and molecular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bridged Bicyclo Compounds, Heterocyclic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cohort Studies

Share to Isocitrate Dehydrogenase

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Nucleophosmin

Share to Prognosis

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 36054614
DOI: 10.1002/ajh.26694
PMCID: PMC13331006

Genes

NPM1
IDH1
IDH2
ELN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.PMID 36054614Read ↗

Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia.Semantic proximity Read ↗

Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study.Semantic proximity Read ↗

Co-mutation landscape and its prognostic impact on newly diagnosed adult patients with NPM1-mutated de novo acute myeloid leukemiaSemantic proximity Read ↗

Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based TherapiesSemantic proximity Read ↗

Prognostic significance of concurrent gene mutations in intensively treated patients withIDH-mutated AML: an ALFA studySemantic proximity Read ↗

Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.Semantic proximity Read ↗

Isocitrate dehydrogenase (IDH) 1 and 2 mutations predict better outcome in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: a study of the ALWP of the EBMT.Semantic proximity Read ↗

IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy.Semantic proximity Read ↗

Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis.Semantic proximity Read ↗

Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia.Semantic proximity Read ↗

The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment.Semantic proximity Read ↗

Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registrySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.